ConclusionsClinical outcome of AIT depends on induction of blocking antibodies able to prevent the patient 's own IgE from allergen binding. Monitoring of clinical efficacy seems to be best achieved using the inhibition mediator release assay, as development of relevant blocking antibodies can be verified in a patient-tailored manner. (Source: Clinical and Translational Allergy)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2y6Ndnd
Κυριακή 7 Οκτωβρίου 2018
Does clinical outcome of birch pollen immunotherapy relate to induction of blocking antibodies preventing IgE from allergen binding? A pilot study monitoring responses during first year of AIT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.